Expert in the development and commercialization of medical device products for 25 years, Yelena Tropsha, PhD, joins Contraline as Chief Technology Officer
Dr. Tropsha will lead efforts to bring Contraline’s male contraceptive device, ADAM™towards FDA approval
CHARLOTTESVILLE, Virginia, March 30, 2022–(BUSINESS WIRE)–Contraline, Inc., a venture-backed medical device company dedicated to providing men with durable, safe and effective contraception, has named medical device industry leader, Dr. Yelena Tropsha, as Chief Technology Officer.
This press release is multimedia. View the full press release here: https://www.businesswire.com/news/home/20220330005043/en/
Dr. Yelena Tropsha joins Contraline as Chief Technology Officer (Photo: Business Wire)
Dr. Tropsha brings more than 25 years of medical device experience to Contraline, from initial innovation through commercialization. Dr. Tropsha worked for 10 years at Coloplast as Vice President of Implantable Devices, Urology, where she was responsible for R&D, clinical, medical and regulatory affairs. Dr. Tropsha has also held VP positions at leading medical device companies DYSIS Medical and Neuronetics and senior technical positions at Medtronic and Becton Dickinson.
During her career, Dr. Tropsha has been involved in the development, approvals and launches of 19 Class II and Class III medical devices in urology and gynecology. In addition to medical device development, his expertise is in materials science with a focus on polymers and biomaterials. She is listed as an inventor on more than 25 patents and 20 publications.
“Yelena joins our team at an exciting time ahead of our first-in-man clinical trial of ADAM™, the world’s first injectable hydrogel designed to provide long-lasting, non-permanent vascular occlusion for men,” said Kevin Eisenfrats, Co. -Founder and CEO of Contraline.
“We are paving the way to bring a breakthrough reproductive medical device like ADAM™ to market. We are also beginning to expand the potential uses of our hydrogel platform. We will greatly benefit from Yelena’s experience leading many companies. with innovative medical devices in urology and gynecology to successful regulatory and commercial outcomes.
At Contraline, Dr. Tropsha will lead R&D, regulatory affairs and market access. She will also lead efforts to expand the use of Contraline’s proprietary hydrogel platform for new indications in reproductive health beyond vas-occlusion.
“I am thrilled and honored to be part of the Contraline team, which represents a new era in contraceptive technologies. Contraline’s work to develop a hydrogel for vascular occlusion is inspired by my areas of interest and “expertise: medical device development, urology and polymer science. The opportunity to take the ADAM™ product from preclinical studies to commercialization will be a highlight of my career,” said Yelena Tropsha.
Dr. Tropsha holds an MSc in Chemistry and a PhD in Polymer Science from Moscow State University in Russia.
Contraline, Inc. is a venture-backed medical device company dedicated to providing men and couples with durable, safe and effective contraception. The company is developing ADAM™, the world’s first injectable hydrogel designed to provide long-lasting barrier contraception to men. The company was founded in 2015 by Kevin Eisenfrats and Dr. John Herr, and is based in Charlottesville, Virginia. To learn more, visit http://www.contraline.com
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220330005043/en/